HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 08-09-2013, 02:08 PM   #1
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
vaccine trial

Went up to Baltimore to Union Medstar hospital and was bled to see if I was a candidate for the Walter Reed vaccine trial. They called today and I'm (I think what she said)HAL2 positive, so I'm not able to join the trial. Are there any others?

Thanks Valleygirl
valleygirl is offline   Reply With Quote
Old 08-09-2013, 06:58 PM   #2
Jackie07
Senior Member
 
Jackie07's Avatar
 
Join Date: Jan 2008
Location: "Love never fails."
Posts: 5,808
Re: vaccine trial

Valleygirl,

Not HAL2 positive? Did you mean Her2?
__________________
Jackie07
http://www.kevinmd.com/blog/2011/06/doctors-letter-patient-newly-diagnosed-cancer.html
http://www.asco.org/ASCOv2/MultiMedi...=114&trackID=2

NICU 4.4 LB
Erythema Nodosum 85
Life-long Central Neurocytoma 4x5x6.5 cm 23 hrs 62090 semi-coma 10 d PT OT ST 30 d
3 Infertility tmts 99 > 3 u. fibroids > Pills
CN 3 GKRS 52301
IDC 1.2 cm Her2 +++ ER 5% R. Lmptmy SLNB+1 71703 6 FEC 33 R Tamoxifen
Recc IIB 2.5 cm Bi-L Mast 61407 2/9 nds PET
6 TCH Cellulitis - Lymphedema - compression sleeve & glove
H w x 4 MUGA 51 D, J 49 M
Diastasis recti
Tamoxifen B. scan
Irrtbl bowel 1'09
Colonoscopy 313
BRCA1 V1247I
hptc hemangioma
Vertigo
GI - > yogurt
hysterectomy/oophorectomy 011410
Exemestane 25 mg tab 102912 ~ 101016 stopped due to r. hip/l.thigh pain after long walk
DEXA 1/13
1-2016 lesions in liver largest 9mm & 1.3 cm onco. says not cancer.
3-11 Appendectomy - visually O.K., a lot of puss. Final path result - not cancer.
Start Vitamin D3 and Calcium supplement (600mg x2)
10-10 Stopped Exemestane due to r. hip/l.thigh pain OKed by Onco 11-08-2016
7-23-2018 9 mm groundglass nodule within the right lower lobe with indolent behavior. Due to possible adenocarcinoma, Recommend annual surveilence.
7-10-2019 CT to check lung nodule.
1-10-2020 8mm stable nodule on R Lung, two 6mm new ones on L Lung, a possible lymph node involvement in inter fissule.
"I WANT TO BE AN OUTRAGEOUS OLD WOMAN WHO NEVER GETS CALLED AN OLD LADY. I WANT TO GET SHARP EDGED & EARTH COLORED, TILL I FADE AWAY FROM PURE JOY." Irene from Tampa

Advocacy is a passion .. not a pastime - Joe
Jackie07 is offline   Reply With Quote
Old 08-09-2013, 09:25 PM   #3
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

This seems interesting. I was in the GP2 arm of the Walter Reed and I was HLA2 positive. sandraGA was negative and received AE37.

my understanding is Phase III is only enrolling lower expressors of HER2, the former 3Ns (Triple Negs) who test HER2+ and HER2++

when was your last infusion of Herceptin?
'lizbeth is offline   Reply With Quote
Old 08-10-2013, 05:27 AM   #4
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
Re: vaccine trial

Hi lizbeth,

My last Herceptin was June 25th. I was really excited about this, what a disappointment.
valleygirl is offline   Reply With Quote
Old 08-10-2013, 05:25 PM   #5
europa
Senior Member
 
europa's Avatar
 
Join Date: Jan 2012
Posts: 362
Re: vaccine trial

I started the vaccine trial here at Sibley about 4 months ago...maybe 6 months ago. I was tested for HLA + or -. I was told that they are only enrolling HLA + patients because they have concluded that HER2+ patients that are HLA - don't benefit from the vaccine. this is what I was told. If you are HER2- and HLA- they put you in the AE37 arm. If you are positive and either HER2+ or - they put you in the GP2 arm.
__________________
DX 10/2011
PET Scan + MRI 10/2011
Lumpectomy 11/11/11
Stage 2B +++ ER+(10%), PR+(5%), HER2+++(1 positive node, 1 micromets to second node)
AC started 12/2011 ended 1/2012
Taxol + Herceptin weekly for 12 weeks ended 4/2012
30 zaps of radiation done 6/2012
Tamoxifen 6/2012
every 3 weeks of Herceptin for another year.
Metformin Trial 8/12
10/12 MRI- CLEAR
01/13 BRAIN MRI- CLEAR!
01/13 Neck MRI- CLEAR!
FINISHED HERCEPTIN 1/9/2013...Woot Woot
Starting Walter Reed Vaccine Trial 2/13
CT Scans + ultrasound of abdomen CLEAR-5/13
02/2015 through 11/2015 emergency D&Cs for Tamoxifen induced uterine polyps which caused uncontrollable hemorrhaging
12/2015 blood clot to left leg caused by Tamoxifen. No longer taking it. On Xarelto, a blood thinner
12/2015 Ablation to prevent hemorrhaging from potential issues with Tamoxifen residue in my system
1/2016 continuing journey without hormonal therapy. Reevaluating the option of a hysterectomy and oopherectomy.
4/1/2018 2mm stroke. Yes, stroke! No cause ever found but they believe it was a migraine that went bonkers and created a tiny clot. No deficits. I was back to normal with 24hrs. Now on baby aspirin for life.
7/27/2018 hysterectomy and oopherectomy
01/07/2019 Mastectomy and expanders put in
3/22/2019 Vtach, almost died. Cause unknown.
7/22/2019 New perky boobs put in
7/21/2020 Off of all drugs but a baby aspirin because of the stroke in 2018.


www.mychemobag.org
www.facebook.com/mychemobag

8 YEARS NED
europa is offline   Reply With Quote
Old 08-10-2013, 06:17 PM   #6
Sandra in GA
Senior Member
 
Join Date: Aug 2009
Location: Moultrie, GA
Posts: 431
Re: vaccine trial

HLA A2- folks do not have a strong response to cancer, organs from others, or stings and bites. The vaccine, AE37 in designed to "more vigoriously" stimulate our bodies to produce antibodies to fight in these situations. The GP2 vaccine, which is also a peptid vaccine, does a good job for HLA A2+ folks, but not for neg ones.

I could not get into a trial at Mayo because they were only looking at the GP2 vaccines with two different additives to increase effectivity. Then I found the Walter Reed study which had both vaccines. That was one of the best days of my life. I traveled 525 miles each way to do the trial and I would do it again in a heart beat.

Please do your best to get into one of these trials. You will never regret it. When I entered the trial you only had a 30 day window from your last Herceptin treatment. They want you to be disease free.

Sandra
__________________
Diagnosed: 7/25/08 ~ age 63, no family history
Surgery: 8/14/08 Bilateral mastectomy; tumor left breast, node dissection; right prophylactic with expanders: 1/12/10 latisimuss dorsi flap on left side: 9/22/10 implants in
Pathology Report: ER/PR-; HER2+ (3+); Grade 3, StageIII; 3cm tumor plus 21/21 lymph nodes positive; 5cm DCIS
Chemo: A/C; Taxol/Herceptin/Tykerb; phase II study at Mayo adding Tykerb for early stage
Radiation: 25 rads
Vaccine: Walter Reed GP2/AE37 vaccine study ~ last booster 9/17/2012
Sandra in GA is offline   Reply With Quote
Old 08-11-2013, 06:47 AM   #7
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
Re: vaccine trial

Hi Sandra in Ga
Can you tell me who your contact is at Walter Reed. I went up to Baltimore on Wednesday and was bled, Friday they called and said I wasn't a candidate because I was HLA positive. I had such high hopes for this vaccine.

Thanks Denise
valleygirl is offline   Reply With Quote
Old 08-11-2013, 11:01 AM   #8
Sandra in GA
Senior Member
 
Join Date: Aug 2009
Location: Moultrie, GA
Posts: 431
Re: vaccine trial

Denise,
I am not sure if the study I am in is still recruiting. I did not go to Walter Reed. There were several locations nationwide with one being in Winston-Salem NC at Wake Forest Medical Center. However, I had a wonderful study nurse and I am certain she will talk with you. Her name is Robin Petro and her number is 336-713-4788. If I were you, I would give her a call and she should be able to share valuable information with you. (Tell her I gave you her name and number.)

Here is the trial info and it looks to me like they are still active. http://clinicaltrials.gov/ct2/show/N...cine%22&rank=1
I do know they have been approved for phase III and are tageting a wider population this time. I do not know the details of this.

I am keeping my fingers crossed for you!!!! Do not give up. Keep looking until you find one that fits your needs. That is the secret.

Sandra
__________________
Diagnosed: 7/25/08 ~ age 63, no family history
Surgery: 8/14/08 Bilateral mastectomy; tumor left breast, node dissection; right prophylactic with expanders: 1/12/10 latisimuss dorsi flap on left side: 9/22/10 implants in
Pathology Report: ER/PR-; HER2+ (3+); Grade 3, StageIII; 3cm tumor plus 21/21 lymph nodes positive; 5cm DCIS
Chemo: A/C; Taxol/Herceptin/Tykerb; phase II study at Mayo adding Tykerb for early stage
Radiation: 25 rads
Vaccine: Walter Reed GP2/AE37 vaccine study ~ last booster 9/17/2012
Sandra in GA is offline   Reply With Quote
Old 08-11-2013, 12:30 PM   #9
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

6/12/2013 Generex Announces Interview of MD Anderson's Dr. Elizabeth Mittendorf, Principal Investigator on Company's AE37 Phase IIb Breast Cancer Efficacy Trial

Unique abilities of AE37 to activate immune system highlighted

WORCESTER, Mass. and TORONTO, June 12, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced an interview given by Dr. Elizabeth Mittendorf, M.D., Ph.D. Dr. Mittendorf is the Principal Investigator of the Company's AE37 clinical trial to test the ability of the novel immunotherapeutic agent to prevent relapse in patients who have had HER2-expressing breast cancer, the largest Phase IIb peptide clinical trial conducted to date. AE37 is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The interview was conducted by Oncology TV at this year's Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago from May 31 to June 4. The interview can be viewed online at:

http://www.oncology.tv/Videos/TabId/79/VideoId/474/ASCO-2013-Elizabeth-A-Mittendorf-MD-PhD-HER2-Peptide-Vaccine.aspx

The interview of Dr. Mittendorf, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gave an overview of this year's ASCO presentations on AE37, as well as where the breast cancer vaccine fits into the field of cancer immunotherapy. She noted that cancer immunotherapy in general was much more in the limelight at this year's conference. She described the two distinguishing features of AE37 that set it apart from other types of cancer vaccines. Firstly, the vaccine is designed to stimulate CD4+ T helper cells, which are key in generating a more robust anti-tumor immune response. Secondly, the vaccine includes a proprietary modification that increases its potency. The studies that were part of this year's ASCO meeting confirm these unique properties. Dr. Mittendorf was also noted that this vaccine addresses patients with any level of HER2 expression, unlike other HER2-targeted therapies. Currently, patients with low HER2 expression represent a patient population of significant unmet need (representing 50% of all breast cancers).

The updates this year built upon interim results of the Company's controlled, randomized Phase IIb clinical trial of AE37 presented at last year's ASCO meeting. Those presentations demonstrated a clear trend toward reduced relapse in breast cancer patients who had received AE37. One of the studies this year showed that while some patients developed a hypersensitivity reaction (urticarial response), they appeared to have a stronger all-around immune response to the AE37 vaccine. Interestingly, no relapses have been observed in this population of patients. A second presentation demonstrated that repeated AE37 boosters could be safely given to patients to further augment and extend the initial anti-tumor immune response observed with AE37.

The primary efficacy analysis of Phase IIb data from the Antigen Express breast cancer study is expected prior to the end of 2013. Mark Fletcher, Generex President & Chief Executive Officer, commented: "Based on the outstanding interim results announced at ASCO 2012, we are looking forward to qualitatively similar results with greater statistical robustness when data is evaluated later this year, which will leave Antigen Express well-positioned to secure a partnership for a Phase III trial." Antigen Express has been encouraged by the US Food and Drug Administration to submit a protocol for the Phase III trial, which the Company is in the process of preparing under the auspices of a Special Protocol Assessment (SPA), whereby the FDA declares the design, clinical endpoints, and statistical analyses acceptable for FDA approval.

Finally, Dr. Mittendorf pointed to the possible real benefit of combining AE37 with other agents, such as immune checkpoint inhibitors. In particular, inhibitors of PD-1 (programmed cell death protein 1) or CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) have been shown to essentially take the brakes off the immune system, allowing it to more effectively combat tumor cells in a general way. As AE37 activates the immune system to specifically attack tumor cells, essentially "stepping on the gas", it is an exciting hypothesis to try combining them. It should be noted, however, that patients treated with AE37 alone also appear to have "taken the brakes off" the immune system to an extent.

http://www.antigenexpress.com/news_r...asp?NewsID=194
'lizbeth is offline   Reply With Quote
Old 08-11-2013, 12:36 PM   #10
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
Re: vaccine trial

Anyone know about the vaccine trial at the University of Pennsylvania with Dr. Czerniecki?

Denise
valleygirl is offline   Reply With Quote
Old 08-11-2013, 12:40 PM   #11
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

Note the Phase IIb says there is a clear trend of effectiveness with AE37, and in the robust responders there have been NO recurrences.

I don't know abou twhat works for your nurse SandraGA, but not having a recurrence works for me!

Valleygirl,

Here is my nurses' email for the Walter Reed AE37 & GP2 trial. You can email her and double check the status:

sherri.thomas.ctr@amedd.army.mil
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease

Last edited by 'lizbeth; 08-11-2013 at 12:41 PM.. Reason: omission
'lizbeth is offline   Reply With Quote
Old 08-11-2013, 12:42 PM   #12
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

6/5/2013 Generex Announces ASCO Presentations of AE37 Vaccine Data; Potential Leading Immunotherapy Option for Breast Cancer Patients

Treatment Regimen Targets All HER2 Expressing Patients, including those 50% of patients for whom no therapies are available

WORCESTER, Mass. and TORONTO, June 5, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced two presentations showing the strengths of AE37 as a viable and promising treatment option for patients who have had breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The two presentations were made at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago from May 31 to June 4.

The two presentations focused on the safety and long-term immunity that can be achieved with AE37 treatment. The first presentation, "Risk factors for development of delayed urticarial reactions in the phase II trial of HER2 peptide vaccines plus GM-CSF versus GM-CSF alone in high-risk breast cancer patients to prevent recurrence", by Alfred Trappey et al, reports on cumulative safety data from the ongoing Phase II efficacy study. The maximum toxicities observed (allergic reactions) occur very infrequently, are easily managed, and have no long-term consequences. In addition, they were observed both in the control arm of the study as well as in the peptide arm, indicating that they were associated with the GM-CSF adjuvant rather than the peptide. The demonstrated safety of AE37 in this larger Phase II patient population confirms prior observations from earlier previous Phase I studies.

"I am very pleased with the progress Antigen Express has made over the years, particularly with the AE37 vaccine program," stated Richard Purcell, Chief Operating Officer of Antigen Express. "The AE37 data continues to track positively, as shown by the immunological and safety results presented in Chicago this week. Given the buzz, excitement, and significant focus on immunotherapy at ASCO this year, a big pharma partnership is a realistic expectation for the Company in the near future."

The second presentation extended results from a published 2013 ASCO abstract, ("Effect of immunization with Ii-Key modified HER2 (776-790) peptide vaccine (AE37) on immunologic responses in prostate cancer patients", by Sonia Perez et al) showing that AE37 induced immunological responses for longer time periods than have been observed with any other peptide vaccines used for breast cancer. In particular, the recent presentation "Booster inoculations of the AE37 peptide vaccine enhance immunological responses in a phase II study", by Eleftheria Anastasopoulou et al, showed that administration of AE37 as a booster for up to two years after the initial therapy further increased the level of specific anti-tumor immunity that could be observed in patients. Not only can the specific immune response be maintained but is even augmented by subsequent dosing.

The strong safety profile and superior immunogenicity set AE37 apart, both from other types of immunotherapy as well as other peptide immunotherapies targeting breast cancer. Combined with highly encouraging interim results, showing a reduction of relapse in patients treated with AE37 in a controlled, randomized Phase II efficacy trial, these latest studies support ongoing plans the Company has for a pivotal Phase III registration trial.

"Several distinct products are being developed with the Antigen Express Ii-Key technology and are at various stages of development," said Joe Moscato of Company consultant Seahawk Capital Partners, Inc. "Our attendance at ASCO 2013 gave Antigen Express the opportunity to initiate and continue discussions with multiple interested prospective big pharma partners and collaborators. The different products have applicability in diseases such as breast cancer, prostate cancer, ovarian cancer, influenza, and HIV. Interim data from October of 2011 suggested efficacy in our AE37 breast cancer vaccine, enhanced with our proprietary Ii-Key/HER2 antigen hybrid, has helped to validate Antigen Express' Ii-Key technology overall." Mr. Moscato went on to say: "The Ii-Key hybrid technology allows tumor-associated or foreign antigens, like viral antigens, to potently enhance the immune system's ability to recognize and destroy cancerous or virus-infected cells bearing any of the targeted antigens, as well as generate immunological memory. We are committed to finding alliances and partners to work together on the best clinical trial programs for each distinct product and, as the end of this year approaches, and new data is unveiled in our late-stage Phase IIb breast cancer trial, we are looking to have sufficient positive data to attract and finalize key partnerships and collaborations."
'lizbeth is offline   Reply With Quote
Old 08-11-2013, 01:06 PM   #13
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

http://www.clinicaltrials.gov/ct2/re...=Open&no_unk=Y

I see about 14 vaccine trials on clinicaltrials.gov

The PRESENT trial has only a 30 day window, and is only for lower expressors. That is trial #10 on the list. Perhaps a Phase II is still open at some locations. E75 is showing about a 43% reduction in recurrence rates.

I'm only familiar with AE37, E75, and GP2 (personal experience) vaccines. I see several new vaccines in a Phase I at one location. So if they are close, or you are willing to travel they could be possibilities.

If you are HLA-A2+ you should be eligible for the GP2, and according to clinicaltrials.gov - it is still in PhaseII and open.

I don't know about the Pennsylvania location vaccine, but would be eager to learn more about it. It might have come up before, but I don't recall.

There must be an opportunity for a vaccine trial for you. Totally worth it with the lowered recurrence rates.

Last edited by 'lizbeth; 08-11-2013 at 01:20 PM.. Reason: addition
'lizbeth is offline   Reply With Quote
Old 08-11-2013, 02:37 PM   #14
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
Re: vaccine trial

Thanks lizbrth for all the info! penniesinaction.org this is the website where I found the info but can't find on the clinical trial pages.
valleygirl is offline   Reply With Quote
Old 08-11-2013, 07:51 PM   #15
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

http://www.ncbi.nlm.nih.gov/pubmed/22252842

Oh the pennies in action has been discussed before. I've forgotten the details but here is a journal article in pub med.
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
'lizbeth is offline   Reply With Quote
Old 08-11-2013, 09:37 PM   #16
Catia
Member
 
Catia's Avatar
 
Join Date: Jul 2013
Posts: 19
Re: vaccine trial

hi.
I am also in the GP2 arm of the trial due to having tested HLA2-positive,. I am enrolled at MD Anderson in Houston and as far as I know they are still looking for participants for it.
__________________
Dx: April1st (yes April Fool's Day!), 2011
ER-/PR-/HER2+++ Tumor grade 3 size:1.6mmx1.2mm
Micromet to sentinel node, 5 auxiliary nodes were clear, stage 1B
April 13th, 2011 Double Mastectomy, no immediate reconstruction
May 2011 to Nov, 2011 chemo AC-TH plus
Herceptin until Sep 2012
11/2012 Began GP-2 vaccine at MD Anderson in Houston (monthly shots until April 2013), now receiving booster shots every six months

Began natural breast reconstruction with BRAVA procedure in Oct 2012
With Dr. Khouri at the Miami Breast Center.

Oct 2012 First fat graft
Jan 2013 Second fat graft
March 2013 Third fat graft
July 2013 Final touch-up with nipple reconstruction
November 2013: Vaccine Booster #1
January 2014 Nipple tatooing
April 2014: Vaccine Booster #2
October 2014: Vaccine Booster #3
April 2015: Vaccine Booster #4 (trial finished)
Dec 2015: Scar treatment with Kenalog and laser

Update: 2022 still in the clear and the GP-2 vaccine trial I participated in is moving to 3rd and final phase. None of the women that are in it have relapsed!!!
Catia is offline   Reply With Quote
Old 08-12-2013, 01:56 PM   #17
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

I asked the San Antonio Med Ctr nurses for the latest status of the clinical trials and here is my understanding of what is open for Her2 3+ (which is us, the Her2+++).

Walter Reed Vaccine trial:

"If a patient is HER2 3+ and HLA A2+ then she would qualify for the study. If she is Her2 3+ and HLA A2-she would NOT qualify for the study. Don't forget there are several other inclusion/exclusion criteria that she may have not met. Also, there are only 3 sites open to enrollment at this time due to the trial being almost fully enrolled and Walter Reed is not one of them. It is us at SAMMC, MD Anderson in Houston and I can't remember the 3rd at this time, but I will ask and let you know.

At this time you can still enroll for AE37 at MD Anderson. They are looking to close the trial to enrollment by the end of the year.
" (this is the Phase II HER2 3+ HLA A2- group).

So it appears that the "not qualifying" is based on full enrollment at specific sites.

Last edited by 'lizbeth; 08-12-2013 at 01:58 PM.. Reason: addition & clarification
'lizbeth is offline   Reply With Quote
Old 08-12-2013, 06:56 PM   #18
Sandra in GA
Senior Member
 
Join Date: Aug 2009
Location: Moultrie, GA
Posts: 431
Re: vaccine trial

Hey, 'lizbeth! No recurrance is what I am all about!!!

When I had my scare in Dec. with a couple of spots on my right lung, I called my study nurse and she emphatically stated she was sure they were nothing ~ and she was right!

Sandra
__________________
Diagnosed: 7/25/08 ~ age 63, no family history
Surgery: 8/14/08 Bilateral mastectomy; tumor left breast, node dissection; right prophylactic with expanders: 1/12/10 latisimuss dorsi flap on left side: 9/22/10 implants in
Pathology Report: ER/PR-; HER2+ (3+); Grade 3, StageIII; 3cm tumor plus 21/21 lymph nodes positive; 5cm DCIS
Chemo: A/C; Taxol/Herceptin/Tykerb; phase II study at Mayo adding Tykerb for early stage
Radiation: 25 rads
Vaccine: Walter Reed GP2/AE37 vaccine study ~ last booster 9/17/2012
Sandra in GA is offline   Reply With Quote
Old 08-12-2013, 09:36 PM   #19
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Re: vaccine trial

Sandra you've been quiet lately. Is it flower season?
'lizbeth is offline   Reply With Quote
Old 08-13-2013, 06:29 AM   #20
valleygirl
Senior Member
 
Join Date: Jan 2012
Location: Millsboro, Delaware
Posts: 140
Re: vaccine trial

anyone doing these....NCT00195091 or NCT00393783
valleygirl is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:09 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter